Exonate is a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases which may lead to vision loss. Our lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. The asset met all endpoints and displayed encouraging signals of efficacy in diabetic patients with retinal eye disease (diabetic macular oedema) in a Phase Ib/IIa trial.
View Top Employees from EXONATE LIMITEDWebsite | http://exonate.com/ |
Revenue | $2 million |
Funding | $6.8 million |
Employees | 21 (12 on RocketReach) |
Founded | 2013 |
Phone | +44 1223 734710 |
Technologies |
JavaScript,
HTML,
Twitter
+11 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biopharma, Manufacturing, Biotechnology, Health Care, Science and Engineering, Health Diagnostics, Pharmaceutical |
Web Rank | 16 Million |
Keywords | Loic Lhuillier, Exonate, David Bates, Exonate |
Competitors | Biokine Therapeutics Ltd., International Therapeutics Inc, Karus Therapeutics Limited, Step Pharma, Welichem Biotech Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular EXONATE LIMITED employee's phone or email?
The EXONATE LIMITED annual revenue was $2 million in 2024.
Loïc Lhuillier is the COO of EXONATE LIMITED.
12 people are employed at EXONATE LIMITED.
The NAICS codes for EXONATE LIMITED are [325, 32, 32541, 3254].
The SIC codes for EXONATE LIMITED are [283, 28].